Patents Represented by Attorney SaraLynn Mandel
  • Patent number: 5416260
    Abstract: Homologous recombination is employed to inactivate genes, particularly genes associated with MHC antigens. Particularly, the .beta..sub.2 -microglobulin gene is inactivated for reducing or eliminating Class I MHC antigens. The resulting cells may be used as universal donors. In addition, embryonic stem cells may be modified by homologous recombination for use in producing chimeric or transgenic mammalian hosts, which may be used as source of universal donor organs.
    Type: Grant
    Filed: November 9, 1990
    Date of Patent: May 16, 1995
    Assignee: University of North Carolina at Chapel Hill
    Inventors: Beverly H. Koller, Oliver Smithies
  • Patent number: 5413923
    Abstract: Homologous recombination is employed to inactivate genes, particularly genes associated with MHC antigens. Particularly, the .beta..sub.2 -microglobulin gene is inactivated for reducing or eliminating Class I MHC antigens. The resulting cells may be used as universal donors. In addition, embryonic stem cells may be modified by homologous recombination for use in producing chimeric or transgenic mammalian hosts, which may be used as source of universal donor organs, or as models for drug and transplantation therapies.
    Type: Grant
    Filed: December 11, 1992
    Date of Patent: May 9, 1995
    Assignees: Cell Genesys, Inc., Univ. of North Carolina at Chapel Hill
    Inventors: Raju Kucherlapati, Beverly H. Koller, Oliver Smithies
  • Patent number: 5144021
    Abstract: A method and media for producing bacterial cellulose under agitated culture conditions resulting in sustained production over an average of 70 hours of at least 0.1 g/liter per hour are achieved. A unique reticulated cellulose product is produced using the methods and conditions claimed, and may be in the form of a sheet characterized by substantial resistance to densification and great tensile strength when produced by sheet forming means.Strains of Acetobacter that are stable under agitated culture conditions and that exhibit substantially reduced gluconic and keto-gluconic acid production are described.
    Type: Grant
    Filed: January 30, 1991
    Date of Patent: September 1, 1992
    Assignee: Weyerhaeuser Company
    Inventors: Ben-Bassat Arie, Robert Bruner, Sharon Shoemaker, Yehoshua Aloni, Harry Wong, Donald C. Johnson, Amar Neogi
  • Patent number: 5137877
    Abstract: The present invention provides novel N-substituted hydrazine bifunctional compounds, novel N-subhstituted hydrazone derivatives of a cytotoxic reagent incorporating the bifunctional compounds, novel conjugates containing at least one cytotoxic reagent molecule reacted with the bifunctional compound and bound to a molecule reactive with a target cell population, methods for their production, and pharmaceutical compositions and methods for delivering cytotoxic reagents to a target population of cells. The hydrazone bonds of the conjugates of the invention permit the release of free cytotoxic reagent from the conjugates in the acidic external or internal environment of the target cells. The bifunctional compounds, derivatives, conjugates and methods of the invention are useful in antibody-or ligand-mediated drug delivery systems for the perferential killing of a target cell population to treat diseases such as cancers, infections and autoimmune disorders.
    Type: Grant
    Filed: May 14, 1990
    Date of Patent: August 11, 1992
    Assignee: Bristol-Myers Squibb
    Inventors: Takushi Kaneko, David Willner, Ivo Monkovic, Robert S. Greenfield, Gary R. Braslawsky
  • Patent number: 5135956
    Abstract: A method for treating or preventing neuronal injury in a mammal, comprising the step of administering in vivo a therapeutically effective amount of a long-chain fatty alcohol having from about 23 to about 29 carbon atoms or prodrug esters thereof. Also disclosed are pharmacological compositions containing from 0.01 mg/kg to about 20 mg/kg of the fatty alcohol. The method and compositions are useful in: treating traumatic injury, chemical injury and injury due to disease; promoting and accelerating recovery of behavioral function after such injury; preventing neuronal injury or death; improving training and memory functions; and protecting neurons against injury.
    Type: Grant
    Filed: October 13, 1989
    Date of Patent: August 4, 1992
    Assignee: The Regents of the University of California
    Inventors: Jacques Borg, Carl W. Cotman, J. Patrick Kesslak
  • Patent number: 5134075
    Abstract: The present invention is concerned with a novel monoclonal antibody which binds strongly to a protein antigen associated with human tumors, including carcinomas of the colon, breast, ovary and lung, as well as melanomas and sarcomas. The antibody binds to normal human cells to a much lesser degree than to tumor cells. The antibody finds use both in diagnostic methods such as the detection of malignant cells associated with tumors and in therapeutic methods for treatment of humans with tumors. Also disclosed is a novel 100,000 dalton glycoprotein antigen found on the cell surface of human tumor cells. The amino terminal amino acid sequence of this antigen is: ##STR1## in which X represents an unidentified amino acid.
    Type: Grant
    Filed: February 17, 1989
    Date of Patent: July 28, 1992
    Assignee: Oncogen Limited Partnership
    Inventors: Karl E. Hellstrom, Ingegerd Hellstrom, Hans Marquardt, Yoshitaka Yoneyama
  • Patent number: 5110600
    Abstract: Retrovirally-infected cells are selectively killed as compared with uninfected cells using an effective amount of amino acid analogs of naturally occurring amino acids, such as L-canavanine (an analog of arginine).
    Type: Grant
    Filed: January 25, 1988
    Date of Patent: May 5, 1992
    Assignee: The Regents of the University of California
    Inventor: Melvin H. Green
  • Patent number: 5084560
    Abstract: Novel pH-sensitive immunoconjugates which dissociate in low-pH tumor tissue, comprising a chemotherapeutic agent and an antibody reactive with a tumor-associated antigen are described. The chemotherapeutic agent is coupled to the antibody by a link which is unstable in low pH. The link may comprise a spacer consisting of a polyamino acid. Representative antibodies for use in these immunoconjugates include monoclonal antibodies which are not internalized by tumor cells.
    Type: Grant
    Filed: August 7, 1990
    Date of Patent: January 28, 1992
    Assignee: Oncogen
    Inventors: Karl E. Hellstrom, Ingegerd E. Hellestrom, Efraim Lavie
  • Patent number: 4997913
    Abstract: Novel pH-sensitive immunoconjugates which dissociate in low-pH tumor tissue, comprising a chemotherapeutic agent and an antibody reactive with a tumor-associated antigen are described. The chemotherapeutic agent is coupled to the antibody by a link which is unstable in low pH. The link may comprise a spacer consisting of a polyamino acid. Representative antibodies for use in these immunoconjugates include monoclonal antibodies which are not internalized by tumor cells.
    Type: Grant
    Filed: May 12, 1987
    Date of Patent: March 5, 1991
    Assignee: Oncogen
    Inventors: Karl E. Hellstrom, Ingegerd E. Hellstrom, Efraim Lavie
  • Patent number: 4859474
    Abstract: A process for producing fructose sweetened cereal products by enzymatically converting a portion of the cellulose fraction in a cereal comprising cereal; fiber to fructose using cellulase and glucose isomerase is claimed. The process may be carried out at moisture contents exceeding 25% (w/w) and moisture contents between about 40% to 80% are preferred.
    Type: Grant
    Filed: September 28, 1987
    Date of Patent: August 22, 1989
    Assignee: Nabisco/Cetus Food Biotechnology Research Partnership
    Inventors: Saul L. Neidleman, John A. Maselli
  • Patent number: 4792407
    Abstract: A method of oxidizing organic compounds in aqueous solutions by using in combination ozone, hydrogen peroxide and ultraviolet radiation is provided.
    Type: Grant
    Filed: February 18, 1988
    Date of Patent: December 20, 1988
    Assignee: Ultrox International
    Inventors: Jack D. Zeff, Eriks Leitis